12/09/2022 (Agence Europe) – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced on Monday 12 September that it has recommended to the European Commission the authorisation of a bivalent mRNA vaccine developed by Pfizer-BioNTech that targets the SARS-CoV-2 sub-variants of concern BA.4 and BA.5 (Omicron) as well as the original SARS-CoV-2 coronavirus strain (see EUROPE B13012A23). The administration of this ‘Comirnaty’ vaccine is...